OTCMKTS:CPHRF - Cipher Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.98
  • Forecasted Upside: 92.56 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.03
▼ -0.05 (-4.63%)
1 month | 3 months | 12 months
Get New Cipher Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CPHRF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CPHRF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$1.98
▲ +92.56% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cipher Pharmaceuticals in the last 3 months. The average price target is $1.98, with a high forecast of $3.00 and a low forecast of $0.95. The average price target represents a 92.56% upside from the last price of $1.03.
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Cipher Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/17/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/15/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/13/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
3/22/2021Stifel NicolausBoost Price TargetHold$0.85 ➝ $0.95
i
1/19/2021Stifel NicolausLower Price TargetHold$1.00 ➝ $0.85
i
10/6/2020Bloom BurtonReiterated RatingBuy$2.00
i
8/27/2020Echelon Wealth PartnersReiterated RatingBuy$3.00
i
8/16/2020Bloom BurtonReiterated RatingBuy$2.00
i
5/11/2020Stifel NicolausReiterated RatingHold
i
1/22/2020Echelon Wealth PartnersReiterated RatingBuy$4.00
i
11/12/2019Echelon Wealth PartnersReiterated RatingBuy$4.00
i
11/16/2016TD SecuritiesDowngradeBuy ➝ Hold$7.50 ➝ $3.50
i
8/13/2016TD SecuritiesReiterated RatingBuy$7.50
i
8/13/2016GMP SecuritiesReiterated RatingHold
i
(Data available from 4/14/2016 forward)
Cipher Pharmaceuticals logo
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; BRINAVESS, a treatment for sinus rhythms in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-ISOTRETINOIN; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include TRULANCE, a once-daily tablet for the treatment of adults with chronic idiopathic constipation and irritable bowel syndrome with constipation; Trevyent, a drug device combination that delivers treprostinil, the treatment for pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001 for tattoo removal. The company was founded in 2000 and is headquartered in Oakville, Canada.
Read More

Today's Range

Now: $1.03
$1.03
$1.03

50 Day Range

MA: $0.87
$0.69
$1.17

52 Week Range

Now: $1.03
$0.53
$1.17

Volume

2,501 shs

Average Volume

16,663 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cipher Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Cipher Pharmaceuticals in the last year: Bloom Burton, Echelon Wealth Partners, and Stifel Nicolaus.
View the latest analyst ratings for CPHRF.

What is the current price target for Cipher Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Cipher Pharmaceuticals in the last year. Their average twelve-month price target is $1.98, suggesting a possible upside of 91.8%. Echelon Wealth Partners has the highest price target set, predicting CPHRF will reach $3.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $0.95 for Cipher Pharmaceuticals in the next year.
View the latest price targets for CPHRF.

What is the current consensus analyst rating for Cipher Pharmaceuticals?

Cipher Pharmaceuticals currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CPHRF will outperform the market and that investors should add to their positions of Cipher Pharmaceuticals.
View the latest ratings for CPHRF.

What other companies compete with Cipher Pharmaceuticals?

How do I contact Cipher Pharmaceuticals' investor relations team?

Cipher Pharmaceuticals' physical mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company's listed phone number is +1-905-6025840. The official website for Cipher Pharmaceuticals is www.cipherpharma.com.